Cardiovascular events and intensity of treatment in polycythemia vera

Abstract

Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial

    Similar works

    Available Versions